Synopsis:
Tata Elxsi Ltd, gained after the company inaugurated the Bayer Development Centre in Radiology at its Pune facility. The centre, set up in partnership with Bayer, will focus on advanced radiology devices, molecular imaging, and regulatory-compliant healthcare innovations to enhance diagnostic precision and accelerate global market delivery.
A design and technology services stock witnessed a strong move in Wednesday’s session after the company announced the launch of a new healthcare-focused facility in partnership with Bayer.
Tata Elxsi Ltd, with a market capitalization of Rs. 36,285.42 crore, opened at Rs. 5,597.45 against a previous close of Rs. 5,556.90. The stock surged to an intraday high of Rs. 5,863.40, marking a 5.5 percent rise from the previous close.
What’s the News?
Tata Elxsi has inaugurated the ‘Bayer Development Centre in Radiology’ at its Pune facility. This centre, developed in collaboration with Bayer, will focus on co-developing advanced radiology devices and technologies aimed at enabling early and accurate diagnosis of critical illnesses.
With an initial emphasis on Molecular Imaging, the centre integrates design, development, and validation to accelerate time-to-market, enhance cost efficiency, and ensure regulatory compliance.
Leveraging Tata Elxsi’s expertise in healthcare engineering and the strength of the Indian ecosystem, the facility will provide scalable innovation and support Bayer’s global radiology solutions across geographies including the US and EU.
Management Commentary
Dr. Konstanze Diefenbach, Head of Research & Development, Radiology, Bayer, commented: ““Bayer is committed to innovative products and high-quality services in diagnostic imaging, and device innovation plays a critical role in delivering precision and safety in patient care. T
his new centre gives us direct access to specialised engineering capabilities through Tata Elxsi, enabling us to accelerate our pipeline of advanced radiology devices while maintaining the quality and reliability that healthcare providers expect from Bayer.”
Sreevatsa Sahasranaman, Sr. Vice President & Head – Healthcare & Life Sciences, Tata Elxsi, said, “This centre is more than an engineering hub—it is where Bayer’s radiology vision meets Tata Elxsi’s design, AI/ML, and regulatory expertise. Our teams will work together to translate ideas into devices that address real-world diagnostic challenges, with the assurance of safety, compliance, and global scalability.”
Also Read: Jewellery stock in focus after receiving ₹100 Cr order from international clients
Financial Snapshot
On a sequential basis, revenue fell 1.8 percent to Rs. 892 crore in Q1FY26 from Rs. 908 crore in Q4FY25. Operating profit declined 10.1 percent to Rs. 187 crore from Rs. 208 crore. Profit before tax dropped 11.3 percent to Rs. 196 crore from Rs. 221 crore, while net profit decreased 16.3 percent to Rs. 144 crore from Rs. 172 crore.
On an annual basis, revenue slipped 3.7 percent from Rs. 926 crore in Q1FY25 to Rs. 892 crore in Q1FY26. Operating profit contracted 25.8 percent to Rs. 187 crore from Rs. 252 crore. Profit before tax fell 22.2 percent to Rs. 196 crore from Rs. 252 crore, while net profit dropped 21.7 percent to Rs. 144 crore from Rs. 184 crore.
About the Company
Tata Elxsi, headquartered in Bangalore, is a global design and technology services company catering to healthcare, automotive, broadcast, and consumer electronics industries. It operates through a wide network of design studios, development centres, and offices worldwide.
Its Healthcare & Life Sciences division, ISO 13485 certified, partners with leading medical device, pharmaceutical, and technology firms to deliver solutions across the product development lifecycle.
Recognised for expertise in consulting, product design, development, validation, and regulatory compliance, Tata Elxsi is regarded as a trusted player in global technology and healthcare engineering.
Written By Manan Gangwar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
